Therapy with monoclonal antibodies
CS Conner
Monoclonal antibodies (MABs) are an exciting development in the field of clinical immunology. Secreted in large amounts from hybrid myeloma (hybridoma) cell lines, MABs are directed at a specific antigen, such as tumor cell antigens, providing a major advantage over conventional, heterogeneous antisera. MABs have shown promise in the treatment of cancer, producing remission in some patients with leukemia and lymphoma. The future uses of MABs are enormous, including passive immunization against infections and allergies, treatment of autoimmune disease, and specific antibody treatment of drug intoxications. The impact of MAB technology on clinical medicine will be felt in the years to come.
